Pomerantz LLP is investigating potential securities claims on behalf of investors of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) following the failure of a key clinical trial. On July 9, 2026, Ionis disclosed that the Phase-3 CARDIO-TTRansform trial of Wainua, an amyloid cardiomyopathy treatment developed in collaboration with AstraZeneca, did not meet its primary endpoint. The primary endpoint measured the reduction of combined cardiovascular death and recurrent events. Following this disclosure, Ionis's stock price fell $20.19 per share, or 23.9%, to close at $64.27 per share on July 9, 2026.

The investigation concerns whether Ionis and certain of its officers and/or directors engaged in securities fraud or other unlawful business practices. Pomerantz LLP is examining whether the company made materially false or misleading statements to investors prior to the disclosure. The Wainua CARDIO-TTRansform study was the largest trial in the ATTR cardiomyopathy population. AstraZeneca had previously positioned the treatment as a key contributor toward its stated "$80 billion 2030 ambition."

Investors who purchased IONS shares and suffered losses are encouraged to check their eligibility to recover losses. Pomerantz LLP advises affected investors to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The firm handles investigations on a contingency basis with no upfront costs. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as a premier firm in corporate, securities, and antitrust class litigation.

Abbisko Therapeutics Co. Ltd. and AstraZeneca Plc have entered a strategic collaboration to jointly develop a novel combination therapy for patients with EGFR-mutated and PD-L1 positive non-small cell lung cancer (NSCLC). The partnership aims to address a persistent treatment gap for patients who typically derive less benefit from standard EGFR-TKI treatments when their tumors express high levels of PD-L1.

China Clears Phase 1/2 Combination Study

The National Medical Products Administration (NMPA) cleared the investigational new drug (IND) application for the study on May 20, 2026. The multicenter, open-label Phase 1/2 trial will assess the safety and efficacy of combining Abbisko's oral PD-L1 inhibitor, lumipodlin (ABSK043), with AstraZeneca's EGFR-targeted therapy, TAGRISSO (osimertinib).

Abbisko will lead the Phase 2 study, while both companies will share responsibilities for conducting the clinical trial. Lumipodlin is being developed as a potentially first-in-class oral small-molecule PD-L1 inhibitor.

AstraZeneca Expands Collaboration Pipeline

Separately, Hong Kong-based CSPC Pharmaceutical Group announced a collaboration, option, and license agreement with AstraZeneca to develop novel small nucleic acid drug candidates. CSPC will receive a $30 million upfront payment and could earn up to $540 million in development milestones, up to $1.2 billion in sales milestones, and single-digit sales-based royalties.

Under the agreement, the companies will jointly discover and develop preclinical candidates for two renal disease targets. AstraZeneca will have the option to secure exclusive global or ex-China rights to develop, manufacture, and commercialize each program. CSPC will retain development, manufacturing, and commercialization rights in China for one preclinical candidate.

In June, Abbisko Therapeutics announced a new strategic research collaboration and license agreement with Eli Lilly and Co. aimed at discovering and developing innovative medicines across multiple disease targets.